Why an IP Strategy Matters Before Fundraising or Exit
Many startups treat intellectual property as a legal task that can be addressed later. In practice, it plays a central role in how investors, partners, and acquirers assess the long-term value of a company.
Evidence from multiple studies shows that startups with a defined IP strategy raise more capital, secure more partnerships, and achieve higher valuations at exit. The timing is critical. IP decisions taken early in a company’s lifecycle shape how defensible the technology becomes and how attractive the company appears during due diligence.
Investors Evaluate Ownership, Not Just Innovation
Investors rarely fund a technology based solely on its technical promise. They assess whether the company has the ability to own and defend that technology in the market.
Survey data from US startups shows how important this factor is in investment decisions. In the medical device sector, 85% of founders reported that venture capital investors considered patents an important factor when deciding whether to invest.¹
The reason is straightforward. If a company does not protect the technology behind its product, competitors can replicate the idea once the market opportunity becomes clear.
This concern is particularly strong in healthcare and life sciences. Product development cycles are long, regulatory processes are complex, and significant capital is required before a solution reaches the market. Investors, therefore, look for mechanisms that protect the innovation throughout that long development period.
IP Protection Is Linked to Higher Funding Probability
Large datasets of European startups provide strong evidence that intellectual property protection correlates with better funding outcomes.²
Compared with startups that did not file any IP rights:
- companies with IP filings were 2.6 times more likely to raise seed funding
- they were 5.2 times more likely to secure early-stage investment
- startups holding both patents and trademarks were more than 10 times more likely to receive early-stage funding
These findings appear across multiple technology sectors but are particularly relevant for life sciences and medical technology companies, where defensibility of innovation is central to long-term value creation.
For investors, IP signals that the company is building assets that competitors cannot easily replicate.
Intellectual Property Influences Exit Value
The role of IP does not end after the funding phase. It also influences outcomes when startups reach acquisition or IPO stages.
Data from European startup exits shows that companies with registered intellectual property rights are more than twice as likely to reach an exit compared with startups that have no filings.²
The difference also appears in acquisition valuations. One dataset reports median acquisition values of roughly:
- $16 million for startups without IP filings
- around $100 million for startups holding both patents and trademarks
This suggests that companies with clearly defined IP positions become more attractive acquisition targets and are able to command higher valuations.
IP Can Retain Value Even When Startups Fail
Another aspect that investors consider is the residual value of intellectual property.
Studies analyzing failed venture-backed startups show that around 70% of patents owned by failed startups were later sold. In medical device startups, roughly 61% of patents were sold after the company failed.³
This secondary market for patents explains why investors sometimes treat IP as a form of collateral. Even if the company does not succeed commercially, the underlying technology may still retain value.
Lack of IP Governance Creates Operational Risk
The absence of a structured IP strategy not only affects fundraising, but it can also create operational risks that surface later in a company’s lifecycle.
Common problems include:
- unclear ownership of technology developed by founders, employees, or research collaborators
- potential patent infringement due to missing freedom-to-operate analysis
- leakage of trade secrets through weak internal controls
- licensing or ownership issues discovered during acquisition due diligence
Corporate surveys show that 85% of companies consider IP assets as important as or more important than other assets during acquisitions, underlining how critical clear ownership becomes in strategic transactions.²
When these issues are discovered late, they can delay deals, reduce company valuation, or even block transactions entirely.
IP Strategy Should Match the Product Model
Not every healthtech company requires the same approach to intellectual property. The optimal strategy depends on the product type and the competitive dynamics of the market.
For example:
- Medical device and hardware startups often rely heavily on patents because physical designs can be replicated once validated.
- AI and data-driven health solutions may derive their advantage from proprietary datasets, training pipelines, and operational know-how, making trade secrets and data governance more important than patents alone.
- Digital health software companies frequently combine IP protection with regulatory compliance, distribution partnerships, and brand development to build defensibility.
The objective is not to patent everything. The objective is to protect the elements that create real competitive advantage.
IP Determines Who Captures the Value of Innovation
Clinical evidence proves that a health technology works. Intellectual property determines who captures the economic value created by that innovation.
Startups that postpone IP decisions often face difficulties later when investors conduct due diligence, when partners evaluate licensing agreements, or when acquirers examine ownership and enforceability.
Companies that integrate IP strategy early, alongside regulatory planning, product development, and commercialization planning, are generally better positioned to raise capital, form partnerships, and scale.
In healthcare markets characterized by long development timelines and high regulatory barriers, intellectual property is not simply a legal formality. It is part of the infrastructure that enables innovation to translate into durable commercial impact.
Opportunity for Digital Health Startups
The WIPO Global Awards, organized by the World Intellectual Property Organization, recognize startups and SMEs that successfully use intellectual property to create real-world impact.
The program will select 10 awardees — five startups and five SMEs — plus several special mentions. Selected companies receive:
- global visibility across WIPO’s international innovation network
- participation in a two-day workshop in Geneva
- six months of tailored IP and business mentorship
- access to international innovation and investor communities
Digital health applicants are evaluated across four dimensions:
- Business case and IP portfolio – market relevance, scalability, and how effectively IP protects the core innovation
- IP commercialization strategy – how IP supports partnerships, licensing, or market expansion
- IP culture – the degree to which IP awareness informs company decisions
- Societal impact – measurable improvements to health outcomes or healthcare system efficiency
The opportunity is open to startups and SMEs from all 194 WIPO member states, with up to 300 employees and annual revenue below $15 million, offering an innovative product or service protected or being protected by IP rights.
Digital health startups interested in applying can submit their application through R2GConnect here
Sources
- National Bureau of Economic Research — High Technology Entrepreneurs and the Patent System
- European Patent Office & EUIPO — Patents, Trade Marks and Startup Finance Study
- National Bureau of Economic Research — Redeployment of Patents from Failed Startups
